

NEW

The ProReach Program™

Remote care for Prospera™ patients including routine labs, in partnership with a national diagnostics laboratory

Natera's new **ProReach Program** enables you to stay closely connected with your transplant patients. Utilizing our nationwide mobile phlebotomy network, we are now able to draw both Prospera and routine labs remotely, with no additional charge. Additional labs include:

BK Virus DNA PCR Quantitative

Complete Blood Count (CBC)

Comprehensive Metabolic Panel

Cyclosporine Levels

Cytomegalovirus DNA PCR Quantitative

Everolimus, Sirolimus and Tacrolimus

Urinalysis

Urine Protein / Creatinine Ratio

Continuity.
Connection.
Convenience.

Provider set up in two simple steps

Customize how you follow your transplant patients:

- 1 Place Prospera orders in the **Provider Portal**, and indicate **mobile draw**
- 2 Inform your Natera Nurse Coordinator of which patients you'd like to **ADD routine lab work** through a premier diagnostics lab

Option 1


Add routine labs on **ALL** Prospera patients

Option 2

Include routine labs on **SPECIFIC** Prospera patients

After enrollment, what's next?

Once your patients are enrolled in the ProReach Program, Natera will take care of the rest:



Complete care with Prospera

Prospera enables you to:

- **Catch all rejection types in a single blood draw:**
Prospera's unique ability to identify T cell-mediated rejection gives a more holistic view of your patient's rejection status.¹
- **Minimize risk of missing active rejection:**
Prospera is three times less likely to miss an active rejection* than the first-generation donor-derived cell-free DNA test (Negative Predictive Value of 95% vs 84%).^{1,2}
- **More accurately classify active rejection:**
Prospera demonstrated better performance than the first-generation dd-cfDNA test (sensitivity of: 89% vs 59%) to identify patients with active rejection.^{1,2}

JOIN NOW

Enroll all your transplant patients today for peace of mind and timely screening.

Call us +1 650.273.4468

Visit us natera.com/proreach

* 25% prevalence of active rejection

1 Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. *J Clin Med*. 2019;8(1):19.
2 Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. *J Am Soc Nephrol*. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

201 Industrial Road, Suite 410, San Carlos, CA 94070 | Main +1 650.249.9090 | Fax +1 650.730.2272 | natera.com

This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. ©2020 Natera, Inc. All Rights Reserved. PRO_OS_ProReachLaunch_20200407_NAT-8020128

